Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Isotonic solution Clear all

Conditions: Meningococcal Disease
Interventions: MenABCWY, Placebo, MenACWY; Biological · Other
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 305 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Huntsville, Alabama • Jonesboro, Arkansas • Melbourne, Florida + 5 more

Conditions: Atrophic Acne Scar
Interventions: Normal Saline, Artefill; Drug · Device
Lead sponsor: Suneva Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 10
States / cities: Beverly Hills, California • Los Angeles, California • San Diego, California + 7 more

Conditions: Heart Failure With Preserved Ejection Fraction, Iron Deficiency
Interventions: Ferric derisomaltose, Placebo (normal saline); Drug
Lead sponsor: Duke University; Other
Eligibility: 65 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Celiac Disease
Interventions: TIMP-GLIA, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 8
States / cities: Jacksonville, Florida • Meridian, Idaho • Indianapolis, Indiana + 5 more

Conditions: Circulatory Perfusion Disorder, Congenital Heart Disease, Single-ventricle
Interventions: Vasopressin, Arginine, Placebo; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 3 Weeks to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pain
Interventions: normal saline, lidocaine; Drug
Lead sponsor: Akron Children's Hospital; Other
Eligibility: 2 Years to 7 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Acute Kidney Injury
Interventions: 0.9% Normal Saline (0.9% Sodium Chloride) injection, Isolyte S injection; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Lactation
Interventions: Recombinant Human Prolactin, Recombinant human prolactin, Normal Saline; Drug · Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pregnancy, Labor Pain
Interventions: Group A Intravenous bolus of 1000 ml lactated ringers solution, Group B Intravenous bolus bolus 1000 ml lactated ringers solution oxytocin decrease to 1/2 current rate, Group C 125 mL/hr of lactated ringers, Group D 125 mL/hr lactated ringers oxytocin decreased to 1/2 current rate; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 251 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: ICU Acquired Weakness
Interventions: FDY-5301, Placebo; Drug · Other
Lead sponsor: Faraday Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Torrance, California • Gainesville, Florida • Boston, Massachusetts + 2 more

Conditions: Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis, Psoriatic Arthritis, Psoriasis, Ankylosing Spondylitis, Enteropathic Arthritis, Crohn's Disease
Interventions: Herpes Zoster (HZ) Vaccine, Placebo; Biological · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 50 Years and older
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 34
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 27 more

Conditions: Chronic Gout
Interventions: SEL-212 low-dose, SEL-212 high-dose, Normal Saline; Drug · Other
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 19 Years to 80 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 40
States / cities: Anniston, Alabama • Sun City, Arizona • Covina, California + 36 more

Conditions: Diabetic Foot Ulcer
Interventions: BR-AC, Standard Care; Other
Lead sponsor: BioStem Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 11
States / cities: San Francisco, California • Sylmar, California • Torrance, California + 8 more

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ), Placebo DPI; Drug
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 40 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Coronary Artery Disease
Interventions: Cangrelor, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Allergic Rhinitis
Interventions: Grass pollen extract, Placebo injection; Biological · Other
Lead sponsor: Amber Patterson; Other
Eligibility: 15 Years to 24 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Acute Ischemic Stroke
Interventions: Ketamine, Normal Saline, Midazolam injection; Drug · Other
Lead sponsor: Lower Merion Neurology Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Wynnewood, Pennsylvania

Conditions: Allogeneic Hematopoietic Cell Transplantation
Interventions: Alemtuzumab; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Heart Failure, Iron-deficiency
Interventions: Ferric Carboxymaltose, Placebo; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3,065 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 188
States / cities: Alexander City, Alabama • Auburn, Alabama • Mobile, Alabama + 157 more

Conditions: Inflammatory Response
Interventions: Ibuprofen, Placebo/Saline solution; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Adenotonsillar Hypertrophy, Obstructive Sleep Apnea, Tonsillitis, Adenoiditis
Interventions: Normal Saline, Dexmedetomidine; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 3 Years to 16 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adolescent Idiopathic Scoliosis
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 10 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lung Disease
Interventions: Placebo, Xolair; Drug
Lead sponsor: Creighton University; Other
Eligibility: 12 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: Omaha, Nebraska • Albany, New York

Conditions: Coronary Artery Disease, Atherosclerosis, Inflammation, Endothelial Dysfunction
Interventions: Rilonacept, Placebo; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction

IV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron Deficiency

Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease

Early Use of Vasopressin in Post-Fontan Management

Efficacy of IV Lidocaine at Alleviating Pain Associated With Propofol Infusion in Pediatric Patients Undergoing Sedation

Fluid Chloride and AKI in Cardiopulmonary Bypass

Recombinant Human Prolactin for Lactation Induction

The Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes

Evaluation of FDY-5301 in Major Trauma Patients in ICU

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy

A Prospective Trial of Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AC

Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators

PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment

Safety of Lymph Node Injection for Allergen Immunotherapy

Quelling of Excitotoxicity in Acute Stroke With Ketamine

Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study

Effect of Intravenous Ibuprofen on Inflammatory Responses in Patients Undergoing Surgery With General Anesthesia.

The Effect of Dexmedetomidine on Airway Complications After Deep or Awake Extubation

Does Tranexamic Acid Decrease Blood Loss in Pediatric Idiopathic Scoliosis Surgery?

Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair

Rilonacept to Improve Artery Function in Patients With Atherosclerosis